Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Dr. Mandaviya also laid the foundation stone for an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur
An accomplished R&D leader and champion of the application of AI to drug discovery
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
The company disclosed that several employees of a subsidiary had their business email addresses stolen
Automated parallel capillary electrophoresis system simplifies protein analysis
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
Microdosing has emerged as a key trend in the pharmaceutical and nutritional markets
Subscribe To Our Newsletter & Stay Updated
